Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On January 2, 2020, Aridis Pharmaceuticals, Inc. (the "Company") announced that Michael A. Nazak was appointed Chief Financial Officer of the Company, effective January 1, 2020. Mr. Nazak succeeds Fred Kurland who resigned for personal reasons on December 31, 2019. Mr. Kurland's resignation was not a result of any disagreement with the Company. Mr. Kurland has agreed to continue to support the Company as a consultant. A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K.

Mr. Nazak is a seasoned financial executive with extensive experience managing teams of finance professionals at healthcare dedicated companies. Prior to joining the Company as Vice President, Finance, he served as Senior Vice President, Finance at Coherus Biosciences, Inc., a publicly listed company on Nasdaq. Previously he was the Senior Director of Finance & Accounting at InteKrin Therapeutics Inc., a biopharmaceutical company. Prior to that, Mr. Nazak served as the Corporate Controller for Reliant Technologies, Inc., a developer and manufacturer of medical laser devices, and as a Senior Director of Finance & Corporate Controller at Connetics Corporation, a then publicly-traded specialty pharmaceutical company. Mr. Nazak also held Corporate Controller and other finance and accounting positions at Cygnus Solutions (a Red Hat company), and MIPS Computer Systems, and was previously an auditor with Coopers & Lybrand LLP. Mr. Nazak is a Certified Public Accountant (inactive), and holds a B.S. degree in Business Administration with a concentration in Accounting from San Jose State University.

Item 9.01. Financial Statements and Exhibits






(d) Exhibits.



    99.1       Press Release of Aridis Pharmaceuticals, Inc. dated January 2, 2020




                                      -2-

© Edgar Online, source Glimpses